<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353857</url>
  </required_header>
  <id_info>
    <org_study_id>19604</org_study_id>
    <secondary_id>2017-002792-26</secondary_id>
    <nct_id>NCT03353857</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam</brief_title>
  <official_title>Open-label, Randomized, Fixed Sequence Cross-over Study With Five Parallel Treatment Arms and Three Treatment Periods to Quantify the Drug-drug Interactions of Two Rifampicin Dose Strengths on Four Progestins and a Fixed Progestin-ethinylestradiol Combination Compared With Midazolam in Healthy Post-menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Quantify the effect of a probe CYP3A4 inducer (Rifampicin) on the pharmacokinetics of
      levonorgestrel, norethindrone, desogestrel, dienogest, drospirenone,estradiol and midazolam
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">August 3, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from zero to infinity (AUC) of levonorgestrel alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
    <description>If AUC cannot be calculated, AUC(0-tlast) will be used instead as primary variable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of levonorgestrel alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from zero to infinity (AUC) of norethindrone alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
    <description>If AUC cannot be calculated, AUC(0-tlast) will be used instead as primary variable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of norethindrone alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from zero to infinity (AUC) of etonogestrel alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
    <description>If AUC cannot be calculated, AUC(0-tlast) will be used instead as primary variable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of etonogestrel alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from zero to infinity (AUC) of dienogest alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
    <description>If AUC cannot be calculated, AUC(0-tlast) will be used instead as primary variable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of dienogest alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from zero to infinity (AUC) of drospirenone and ethinylestradiol alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
    <description>If AUC cannot be calculated, AUC(0-tlast) will be used instead as primary variable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of drospirenone and ethinylestradiol alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from zero to infinity (AUC) of midazolam alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
    <description>If AUC cannot be calculated, AUC(0-tlast) will be used instead as primary variable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of midazolam alone and in the presents of rifampicin</measure>
    <time_frame>Day 1, Day 15 and Day 26</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Biological Availability</condition>
  <arm_group>
    <arm_group_label>levonorgestrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>levonorgestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>norethindrone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>norethindrone and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>desogestrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>desogestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dienogest</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dienogest and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drospirenone/ ethinylestradiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drospirenone/ethinylestradiol and midazolam will be administered on Day 1, Day 15 and Day 26.
rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levonorgestrel/ Microlut</intervention_name>
    <description>In Period 1, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 1, In Period 2, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 15 In Period 3, 0.03 mg single dose administered as 1x0.03 mg tablet at Study Day 26</description>
    <arm_group_label>levonorgestrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethindrone/ Noriday</intervention_name>
    <description>In Period 1, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 1, In Period 2, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 15 In Period 3, 0.35 mg single dose administered as 1x0.35 mg tablet at Study Day 26</description>
    <arm_group_label>norethindrone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desogestrel/ Cerazette</intervention_name>
    <description>In Period 1, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 1, In Period 2, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 15 In Period 3, 0.075 mg single dose administered as 1x0.075 mg tablet at Study Day 26</description>
    <arm_group_label>desogestrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest/ Visanne</intervention_name>
    <description>In Period 1, 2 mg single dose administered as 1x2 mg tablet on Study Day 1, In Period 2, 2 mg single dose administered as 1x2 mg tablet on Study Day 15 In Period 3, 2 mg single dose administered as 1x2 mg tablet at Study Day 26</description>
    <arm_group_label>dienogest</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drospirenone, Ethinylestradiol/ Yasmin</intervention_name>
    <description>In Period 1, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 1, In Period 2, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 15, In Period 3, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 26,</description>
    <arm_group_label>Drospirenone/ ethinylestradiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam/ Midazolam-ratiopharm</intervention_name>
    <description>In Period 1, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 1, In Period 2, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 15 In Period 3, 1 mg single dose administered as 1x0.5 ml oral solution at Study Day 26</description>
    <arm_group_label>levonorgestrel</arm_group_label>
    <arm_group_label>norethindrone</arm_group_label>
    <arm_group_label>desogestrel</arm_group_label>
    <arm_group_label>dienogest</arm_group_label>
    <arm_group_label>Drospirenone/ ethinylestradiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>In period 2, 10 mg (suspension, 0.5 ml) for 11 days at 10 mg/day In period 3, 600 mg (film-coated tablets) for 11 days at 600 mg/day</description>
    <arm_group_label>levonorgestrel</arm_group_label>
    <arm_group_label>norethindrone</arm_group_label>
    <arm_group_label>desogestrel</arm_group_label>
    <arm_group_label>dienogest</arm_group_label>
    <arm_group_label>Drospirenone/ ethinylestradiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subject based on a complete medical history, physical examination, ECG,
             and clinical laboratory tests

          -  Age: 45 to 70 years (inclusive) at the first screening visit

          -  Minimum body weight 50 kg with Body mass index (BMI) above or equal to 18.5 kg/m², and
             below or equal to 30 kg/m² at the first screening visit

          -  Postmenopausal state, revealed indicated by either:

               -  medical history, if applicable (natural menopause at least 12 months prior to
                  first study drug administration, for women younger than 60 years confirmed by
                  follicle stimulating hormone (FSH) &gt;40 IU/L AND estradiol ≤ 20 pg/mL; or

               -  surgical menopause by bilateral ovariectomy at least 3 months prior to first
                  study drug administration)

        Exclusion Criteria:

          -  Relevant diseases within the last 4 weeks prior to the first study drug
             administration, i.e. any disease requiring treatment by a health-care provider

          -  Febrile illness within 1 week before the first study drug administration

          -  Known severe allergies, non-allergic drug reactions, or multiple drug allergies

          -  Presence or history of thrombosis, thrombophlebitis, thromboembolic diseases of veins
             and/or arteries, e.g. deep vein thrombosis, stroke, myocardial infarction, pulmonary
             embolism, transient ischemic attack, angina pectoris

          -  Presence or history of conditions that increase the risk of thromboembolic diseases,
             e.g. disturbances of the coagulation system, thromboembolic diseases in close
             relatives at age ≤50 years], valvular heart disease, atrial fibrillation, cardiac
             dysfunction)

          -  Presence, history, or suspected presence of malignant tumors or tumors of the liver
             and pituitary

          -  Presence or history of liver disease e.g. disturbances of the bilirubin excretion
             (Dubin-Johnson and Rotor syndromes), cholecystectomy ; cholestasis, idiopathic icterus
             or pruritus during a previous pregnancy or estrogen-progestogen treatment

          -  Relevant kidney diseases or renal injury associated with multisystem
             diseases/disorders, e.g. glomerulonephritis systemic lupus erythematous, diabetic
             nephropathy. A history of a single episode of uncomplicated nephrolithiasis does not
             prevent participation

          -  Known metabolic disorder, e.g. diabetes mellitus, severe hypertriglyceridemia

          -  Migraine with neurologic symptoms

          -  Clinically significant depression, current or in the last year

          -  Known current thyroid disorders which require treatment. Subjects with an euthyroid
             struma who do not need any treatment can participate.

          -  Chronic respiratory insufficiency

          -  History of porphyria

          -  Contraindications for midazolam, e.g. myasthenia gravis, and sleep apnea
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+) 1-888-8422937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For trial location information (Phone Menu Options '3' or '4')</last_name>
    <phone>(+)1-888-84 22937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CRS Clinical-Research-Services Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CRS Clinical-Research-Services Mönchengladbach GmbH</name>
      <address>
        <city>Mönchengladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

